Global Rheumatoid Arthritis Drugs Market 2014-2018

Global Rheumatoid Arthritis Drugs Market 2014-2018

Category : Healthcare
Published On : July  2014
Pages : 94



TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

About Rheumatoid Arthritis
RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA.
TechNavio's analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Rheumatoid Arthritis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of RA that are available in the market. The Global Rheumatoid Arthritis Drugs market can be divided into two segments: Symptomatic and DMARDs. 
TechNavio's report, the Global Rheumatoid Arthritis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Rheumatoid Arthritis Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas 
• EMEA        
• APAC
Key Vendors
• AbbVie Inc.
• Amgen Inc.
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Janssen Pharmaceuticals Inc.
• Pfizer Inc.
Other Prominent Vendors
 
• AB Science SA
• Astellas Pharma Inc.
• AstraZeneca plc
• Biogen Idec Inc.
• Boehringer Ingelheim GmbH
• Celgene Corp.
• Daiichi Sankyo Co. Ltd.
• Eli Lilly & Co.
• GE Healthcare Co.
• Genmab A/S
• GSK plc
• Incyte Corp.
• Merck & Co. Inc.
• Mitsubishi Tanabe Pharma Corp.
• Novartis AG
• Novo Nordisk A/S
• Rigel Pharmaceuticals Inc.
• Sanofi
• Takeda Pharmaceutical Co. Ltd.
• UCB SA
• Vertex Pharmaceuticals Inc.
Key Market Driver
• Increasing Aging Population
• For a full, detailed list, view our report.
Key Market Challenge
• High Cost of RA Treatment
• For a full, detailed list, view our report.
Key Market Trend
• Increase in R&D Activities
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

 

 

 



01. Executive Summary

02. List of Abbreviations

03. Scope of the Report


03.1 Market Overview

03.2 Product Offerings

03.2.1 Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape


06.1 Market Overview

06.2 Market Size and Forecast

07. Competitive Assessment of Top Drugs

08. Five Forces Analysis

09. Market Segmentation by Category

10. Geographical Segmentation

11. Buying Criteria

12. Rate of Incidence and Prevalence


12.1.1 US

12.1.2 UK

12.1.3 Asia

13. Pipeline Snapshot

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape


20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2013

20.3 Other Prominent Vendors

21. Key Vendor Analysis

21.1 AbbVie

21.1.1 Key Facts

21.1.2 Business Description

21.1.3 Product Segmentation

21.1.4 Revenue by Product Line

21.1.5 Revenue Comparison 2012 and 2013

21.1.6 Revenue by Geographical Segmentation

21.1.7 Business Strategy

21.1.8 Key Developments

21.1.9 SWOT Analysis

21.1.10 Strengths

21.1.11 Weaknesses

21.1.12 Opportunities

21.1.13 Threats

21.2 Amgen

21.2.1 Key Facts

21.2.2 Business Overview

21.2.3 Product Segmentation by Revenue 2013

21.2.4 Geographical Segmentation by Revenue 2013

21.2.5 Business Strategy

21.2.6 Key Information

21.2.7 SWOT Analysis

21.2.8 Strengths

21.2.9 Weaknesses

21.2.10 Opportunities

21.2.11 Threats

21.3 Bristol-Myers Squibb

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Product Segmentation

21.3.4 Sales by Geography

21.3.5 Business Strategy

21.3.6 Key Information

21.3.7 SWOT Analysis

21.3.8 Strengths

21.3.9 Weaknesses

21.3.10 Opportunities

21.3.11 Threats

21.4 F. Hoffmann La Roche

21.4.1 Key Facts

21.4.2 Business Overview

21.4.3 Business Segmentation

21.4.4 Business Segmentation by Revenue 2012 and 2013

21.4.5 Sales by Geography

21.4.6 Business Strategy

21.4.7 Key Information

21.4.8 SWOT Analysis

21.4.9 Strengths

21.4.10 Weaknesses

21.4.11 Opportunities

21.4.12 Threats

21.5 Janssen Pharmaceuticals

21.5.1 Key Facts

21.5.2 Business Overview

21.5.3 Business Segmentation

21.5.4 Business Strategy

21.5.5 Key Developments

21.5.6 SWOT Analysis

21.5.7 Strengths

21.5.8 Weaknesses

21.5.9 Opportunities

21.5.10 Threats

21.6 Pfizer

21.6.1 Key Facts

21.6.2 Business Overview

21.6.3 Business Segmentation by Revenue 2013

21.6.4 Business Segmentation by Revenue 2012 and 2013

21.6.5 Sales by Geography

21.6.6 Business Strategy

21.6.7 Key Developments

21.6.8 SWOT Analysis

21.6.9 Strengths

21.6.10 Weaknesses

21.6.11 Opportunities

21.6.12 Threats

22. Other Reports in this Series



List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global Rheumatoid Arthritis Drugs Market 2013-2018 (US$ billion)

Exhibit 3: Competitive Assessment of Top RA Drugs

Exhibit 4: Revenue Share of RA Drugs by Key Vendors 2013

Exhibit 5: Global Rheumatoid Arthritis Drugs Market Segmentation by Treatment Approach

Exhibit 6: Global Rheumatoid Arthritis Drugs Market Segmentation by Treatment Approach 2013

Exhibit 7: Global Rheumatoid Arthritis Drugs Market by Geographical Segmentation 2013

Exhibit 8: Global Rheumatoid Arthritis Drugs Market Share Analysis 2013

Exhibit 9: AbbVie Inc.: Product Segmentation

Exhibit 10: AbbVie Inc.: Revenue by Product Line 2013

Exhibit 11: AbbVie Inc.: Revenue Comparison by Product Line 2012 and 2013 (US$ billion)

Exhibit 12: AbbVie Inc.: Revenue by Geographical Segmentation 2013

Exhibit 13: Amgen: Product Segmentation by Revenue 2013

Exhibit 14: Amgen: Geographical Segmentation by Revenue 2013

Exhibit 15: Bristol-Myers Squibb Co.: Product Segmentation (Based on Therapeutic Areas)

Exhibit 16: Bristol-Myers Squibb Co.: Sales by Geography 2013

Exhibit 17: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013

Exhibit 18: F. Hoffmann-La Roche Ltd: Business Segmentation by Revenue 2012 and 2013

Exhibit 19: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Pharmaceuticals Division)

Exhibit 20: F. Hoffmann-La Roche Ltd: Sales by Geography 2013 (Diagnostics Division)

Exhibit 21: Janssen Pharmaceuticals Inc.: Product Segmentation 2013

Exhibit 22: Pfizer Inc.: Business Segmentation by Revenue 2013

Exhibit 23: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013

Exhibit 24: Pfizer Inc.: Sales by Geography 2013



 



 


Enquiry Before Buy
image
Can´t read the image ? refresh here.